238 related articles for article (PubMed ID: 22753910)
1. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Younes A; Kim S; Romaguera J; Copeland A; Farial Sde C; Kwak LW; Fayad L; Hagemeister F; Fanale M; Neelapu S; Lambert JM; Morariu-Zamfir R; Payrard S; Gordon LI
J Clin Oncol; 2012 Aug; 30(22):2776-82. PubMed ID: 22753910
[TBL] [Abstract][Full Text] [Related]
2. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
3. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Kantarjian HM; Lioure B; Kim SK; Atallah E; Leguay T; Kelly K; Marolleau JP; Escoffre-Barbe M; Thomas XG; Cortes J; Jabbour E; O'Brien S; Bories P; Oprea C; Hatteville L; Dombret H
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):139-45. PubMed ID: 26775883
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
7. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B; Thieblemont C; de Guibert S; Dupuis J; Ribrag V; Bouabdallah R; Morschhauser F; Navarro R; Le Gouill S; Haioun C; Houot R; Casasnovas O; Holte H; Lamy T; Broussais F; Payrard S; Hatteville L; Tilly H
Br J Haematol; 2016 Jun; 173(5):722-30. PubMed ID: 27010483
[TBL] [Abstract][Full Text] [Related]
8. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F; Middeke JM; Janz M; Lenz G; Witzens-Harig M; Bouabdallah R; La Rosée P; Viardot A; Salles G; Kim SJ; Kim TM; Ottmann O; Chromik J; Quinson AM; von Wangenheim U; Burkard U; Berk A; Schmitz N
Invest New Drugs; 2020 Oct; 38(5):1472-1482. PubMed ID: 32172489
[TBL] [Abstract][Full Text] [Related]
10. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma.
Ohmachi K; Ogura M; Suehiro Y; Ando K; Uchida T; Choi I; Ogawa Y; Kobayashi M; Fukino K; Yokoi Y; Okamura J
Int J Hematol; 2019 Jun; 109(6):657-664. PubMed ID: 30915717
[TBL] [Abstract][Full Text] [Related]
12. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
13. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
14. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
Trnĕný M; Verhoef G; Dyer MJ; Ben Yehuda D; Patti C; Canales M; Lopez A; Awan FT; Montgomery PG; Janikova A; Barbui AM; Sulek K; Terol MJ; Radford J; Guidetti A; Di Nicola M; Siraudin L; Hatteville L; Schwab S; Oprea C; Gianni AM
Haematologica; 2018 Aug; 103(8):1351-1358. PubMed ID: 29748443
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Stone MJ; Sausville EA; Fay JW; Headlee D; Collins RH; Figg WD; Stetler-Stevenson M; Jain V; Jaffe ES; Solomon D; Lush RM; Senderowicz A; Ghetie V; Schindler J; Uhr JW; Vitetta ES
Blood; 1996 Aug; 88(4):1188-97. PubMed ID: 8695836
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Ogura M; Hatake K; Ando K; Tobinai K; Tokushige K; Ono C; Ishibashi T; Vandendries E
Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
19. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
